Spots Global Cancer Trial Database for Hyper-CVAD Treatment in Lymphoblastic Lymphoma

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Hyper-CVAD Treatment in Lymphoblastic Lymphoma

Official Title: The Clinical Outcomes of Hyper-CVAD Treatment in Lymphoblastic Lymphoma

Study ID: NCT01813344

Conditions

Lymphoblastic Lymphoma

Interventions

Study Description

Brief Summary: Treatment outcomes of lymphoblastic lymphoma (LBL) have improved by the use of the regimens for acute lymphoblastic leukemia. Hyper-CVAD is one of the most effective treatments with high remission rate in acute lymphoblastic leukemia (ALL) and LBL. However, the treatment outcome of hyper-CVAD in LBL has reported only in small number of patients from single institution. The investigators conducted this study to evaluate the hyper-CVAD regimen based treatment in LBL.

Detailed Description: We will analyze treatment outcome of lymphoblastic lymphoma patients treated with hyper-CVAD regimen from 13 institutions in Korea. In all patients, hyper-CVAD was initial treatment. After achievement of response, patients either underwent hematopoietic stem cell transplantation (HSCT) or consolidation with hyper-CVAD.